A French CD­MO looks to add even more cell and gene ther­a­py ca­pac­i­ty at a Paris-area site

French CD­MO Yposke­si will build its sec­ond com­mer­cial cell and gene ther­a­py fa­cil­i­ty in Cor­beil-Es­sonnes, near Paris, the com­pa­ny an­nounced last week.

The project is dubbed SKY, and will al­so de­vel­op a glob­al re­source for drug de­vel­op­ers of ATMPs. It will cost about $71 mil­lion, and en­com­pass 50,000 square feet up­on com­ple­tion. The Project will cre­ate 80 new jobs, and ad­dress a short­age in man­u­fac­tur­ing ca­pac­i­ty for com­pa­nies look­ing to ad­vance clin­i­cal tri­als and com­mer­cial­ize ther­a­peu­tics, the press re­lease said. The site will have two ad­di­tion­al pro­duc­tion lines and sev­er­al 1,000-liter biore­ac­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Principal

Alexandria Real Estate Equities

Cambridge, MA, USA